Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Buy” from Analysts
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has been assigned an average recommendation of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the […]
More Stories
Maple Gold Mines Ltd. (OTCMKTS:MGMLF) Short Interest Update
Maple Gold Mines Ltd. (OTCMKTS:MGMLF – Get Free Report) saw a significant decline in short interest in the month of...
Mandalay Resources Co. (OTCMKTS:MNDJF) Short Interest Down 87.7% in December
Mandalay Resources Co. (OTCMKTS:MNDJF – Get Free Report) saw a large drop in short interest during the month of December....
Merck KGaA (OTCMKTS:MKGAF) Reaches New 12-Month Low – Here’s Why
Merck KGaA (OTCMKTS:MKGAF – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Thursday ....
BNY Mellon Strategic Municipals, Inc. (NYSE:LEO) Sees Significant Growth in Short Interest
BNY Mellon Strategic Municipals, Inc. (NYSE:LEO – Get Free Report) saw a large growth in short interest in the month...
Short Interest in KOSÉ Co. (OTCMKTS:KSRYY) Expands By 4,300.0%
KOSÉ Co. (OTCMKTS:KSRYY – Get Free Report) was the recipient of a significant increase in short interest in December. As...
Network-1 Technologies (NYSEAMERICAN: NTIP) Enters into 10b5-1 Plan for Share Repurchases
Network-1 Technologies, Inc. (the “Company”) has recently disclosed in its Form 8-K filing that its Board of Directors has approved...